Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
The burden ofADRs on the NHS is high, accounting for considerable morbidity, mortality, and extra costs, and measures need to be put into place to reduce the burden of ADRs and thereby further improve the benefit:harm ratio of the drugs.
Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes
- E. C. Davies, C. F. Green, Stephen Taylor, P. Williamson, D. Mottram, M. Pirmohamed
- MedicinePloS one
- 11 February 2009
It is concluded that approximately one in seven hospital in-patients experience an ADR, which is a significant cause of morbidity, increasing the length of stay of patients by an average of 0.25 days/patient admission episode.
Drug repurposing: progress, challenges and recommendations
- S. Pushpakom, Francesco Iorio, M. Pirmohamed
- Chemistry, BiologyNature Reviews Drug Discovery
- 12 October 2018
Approaches used for drug repurposing (also known as drug repositioning) are presented, the challenges faced by the repurpose community are discussed, and innovative ways by which these challenges could be addressed are recommended to help realize the full potential of drugRepurposing.
Emergence and global spread of epidemic healthcare-associated Clostridium difficile
This analysis identifies key genetic changes linked to the rapid transcontinental dissemination of epidemic C. difficile 027/BI/NAP1 and highlights the routes by which it spreads through the global healthcare system.
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.
- R. Sharma, H. R. McLelland, W. Steward
- Medicine, BiologyClinical cancer research : an official journal of…
- 1 July 2001
The results suggest that Curcuma extract can be administered safely to patients at doses of up to 2.2 g daily, equivalent to 180 mg of curcumin, and that larger clinical trials ofcurcumin has low oral bioavailability in humans and may undergo intestinal metabolism.
Phase I Clinical Trial of Oral Curcumin
A daily oral dose of 3.6 g of curcumin is advocated for Phase II evaluation in the prevention or treatment of cancers outside the gastrointestinal tract in patients with advanced colorectal cancer refractory to standard chemotherapies.
Which drugs cause preventable admissions to hospital? A systematic review.
- R. Howard, A. Avery, M. Pirmohamed
- Medicine, Political ScienceBritish journal of clinical pharmacology
- 1 February 2007
Four groups of drugs account for more than 50% of the drug groups associated with preventable drug-related hospital admissions, and concentrating interventions on these drug groups could reduce appreciably the number of preventable drugs-related admissions to hospital from primary care.
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
Findings provide new insights into the mechanism of flucloxacillin DILI and have the potential to substantially improve diagnosis of this serious disease.
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
- J. Johnson, L. Gong, R. Altman
- Medicine, BiologyClinical pharmacology and therapeutics
- 1 October 2011
The purpose of this article is to assist in the interpretation and use of CYP2C9 and VKORC1 genotype data for estimating therapeutic warfarin dose to achieve an INR of 2–3, should genotype results be available to the clinician.
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.
The presence of the HLA-A*3101 allele was associated with carbamazepine-induced hypersensitivity reactions among subjects of Northern European ancestry.